{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:47:01Z","timestamp":1780534021437,"version":"3.54.1"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2001,12,29]],"date-time":"2001-12-29T00:00:00Z","timestamp":1009584000000},"content-version":"vor","delay-in-days":89,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutic Apheresis"],"published-print":{"date-parts":[[2001,10]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> The Liver Dialysis Unit (the <jats:italic>Unit<\/jats:italic>) is a liver\u2010assist device that employs hemodiabsorption (dialysis of blood against powdered sorbents) to selectively remove numerous small molecular weight toxins of hepatic failure. The Unit has been cleared by the Food and Drug Administration and is indicated and marketed for treatment of acute hepatic encephalopathy (AHE) due to decompensation of chronic liver disease (A\u2010on\u2010C) or fulminant hepatic failure (FHF). Controlled, prospective, and randomized studies of liver dialysis were conducted at several centers, enrolling 56 patients with AHE, grades II\u2013IV with or without renal and respiratory insufficiency or failure. Liver dialysis treatments were for 6 h daily, 1\u20135 days with similar observation periods for control patients. Physiologic status, neurologic status, and outcome (recovery of hepatic function, improvement for transplant, or death) were measured, and results were compared for treated patients versus controls for patients with A\u2010on\u2010C and patients with FHF. Liver dialysis resulted in physiologic and neurologic improvement of patients with AHE, regardless of etiology. Liver dialysis significantly improved the incidence of positive outcomes (recovery of hepatic function or improvement for transplant) of A\u2010on\u2010C patients versus controls (71.5% treated, 35.7% control, p = 0.036), but had an insignificant improvement in the outcome of patients with FHF as compared with the control group. Among the overall 31 treated patients, 51.6% survived. Outcome was not negatively affected by the presence of kidney failure or respiratory failure. The plasmafilter unit (PF\u2010Unit) combines hemodiabsorption with push\u2010pull sorbent\u2010based pheresis (the PF add\u2010on module, with powdered sorbent surrounding plasmafilters). At blood flow rates of 200 ml\/min, the system clears creatinine and aromatic amino acids at 120\u2013160 ml\/min, unconjugated bilirubin at 20\u201340 ml\/min, and cytokines at 15\u201325 ml\/min. The PF\u2010Unit has been tested in a few patients with hepatic failure with Grades III and IV encephalopathy, and respiratory, and kidney insufficiency. Treatment appeared to be safe, and there were no significant hematologic changes. Physiologic changes included improved blood pressure, and encephalopathy, and stable urine output. Chemical changes included a decrease in the plasma levels of bilirubin, aromatic amino acids, ammonium, creatinine, and IL\u20101\u03b2. The PF add\u2010on module adds the capability to the Unit to remove bilirubin and other strongly protein\u2010bound toxins from treated patients and may be of clinical benefit in the management of patients with the most severe hepatic failure and encephalopathy, including patients with FHF or concomitant sepsis.<\/jats:p>","DOI":"10.1046\/j.1526-0968.2001.00384.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T21:00:58Z","timestamp":1047502858000},"page":"404-416","source":"Crossref","is-referenced-by-count":25,"title":["Powdered Sorbent Liver Dialysis and Pheresis in Treatment of Hepatic Failure"],"prefix":"10.1111","volume":"5","author":[{"given":"Stephen R.","family":"Ash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,29]]},"reference":[{"key":"e_1_2_5_2_2","unstructured":"Baig M. Overview of the treatment of fulminant hepatic failure. In: Rose BD ed.UpToDate.Wellesley MA: UpToDate Inc. 2001 (CD\u2010ROM\/Internet Publication)."},{"key":"e_1_2_5_3_2","unstructured":"Ferenci P. Clinical manifestations and diagnosis of hepatic failure. In: Rose BD ed.UpToDate.Wellesley MA: UpToDate Inc. 2001 (CD\u2010ROM\/Internet Publication)."},{"key":"e_1_2_5_4_2","unstructured":"Ash SR. Liver dialysis system for hepatic failure. In: Rose BD ed.UpToDate.Wellesley MA: UpToDate Inc. 2001 (CD\u2010ROM\/Internet Publication)."},{"key":"e_1_2_5_5_2","unstructured":"Ferenci P. Pathogenesis of hepatic encephalopathy. In: Rose BD ed.UpToDate.Wellesley MA: UpToDate Inc. 2001 (CD\u2010ROM\/Internet Publication)."},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.7182\/prtr.1.8.1.625l0438071k6182"},{"key":"e_1_2_5_7_2","first-page":"250","article-title":"A prototype for a hybrid artificial liver.","volume":"24","author":"Hager JC","year":"1978","journal-title":"Trans Am Soc Artif Intern Organs"},{"key":"e_1_2_5_8_2","unstructured":"Ferenci P. Treatment of hepatic encephalopathy. In: Rose BD ed.UpToDate.Wellesley MA: UpToDate Inc. 2001 (CD\u2010ROM\/Internet Publication)."},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)92412-0"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-009-3361-3_3"},{"key":"e_1_2_5_11_2","first-page":"3535","article-title":"Perioperative management of fulminant and subfulminant hepatic failure with therapeutic plasmapheresis.","volume":"21","author":"Munoz JJ","year":"1989","journal-title":"Transplant Proc"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1958.tb85989.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196603032740901"},{"key":"e_1_2_5_14_2","first-page":"63","volume-title":"Ascites and renal dysfunction in liver disease. Pathogenesis, diagnosis and treatment","author":"Ellis AJ","year":"1999"},{"key":"e_1_2_5_15_2","first-page":"701","article-title":"Hepatic failure coma (HFC) treated by polyacrylonitryle membrane (PAN) hemodialysis (HD).","volume":"22","author":"Opolon P","year":"1976","journal-title":"Trans Am Artif Intern Organs"},{"key":"e_1_2_5_16_2","first-page":"892","article-title":"A simple extracorporeal device for reducing elevated blood ammonia levels.","volume":"44","author":"Schechter DC","year":"1958","journal-title":"Surgery"},{"key":"e_1_2_5_17_2","first-page":"83","article-title":"A convenient hemoperfusion microapparatus over charcoal for the treatment of endogenous and exogenous intoxications: its use as an effective artificial kidney.","volume":"1","author":"Yatzidis H","year":"1964","journal-title":"Proc Eur Dial Transplant Assn"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1594.1992.tb00288.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/039139889101400401"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-009-1087-4_20"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90011-X"},{"key":"e_1_2_5_22_2","first-page":"151","article-title":"Clinical effects of adsorbent suspension dialysis system in treatment of hepatic coma (the BioLogic\u2010DT).","volume":"15","author":"Ash SR","year":"1992","journal-title":"Int J Artif Organs"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1594.1994.tb02216.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/039139889401701207"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/039139889902200107"},{"key":"e_1_2_5_26_2","first-page":"529","article-title":"Preliminary results: randomized clinical trial of the BioLogic\u2010DT in treatment of acute hepatic failure (AHF) with coma.","volume":"21","author":"Mazariegos GV","year":"1997","journal-title":"Artif Organs"},{"key":"e_1_2_5_27_2","first-page":"401A","article-title":"A controlled study of the BioLogic\u2010DT System in chronic hepatic encephalopathy.","volume":"28","author":"Kramer L","year":"1998","journal-title":"Hepatology"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1988.tb06300.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1594.1999.06122.x"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.19834"},{"key":"e_1_2_5_31_2","unstructured":"Bem DS Sherman JD Napolitano A Leon\u2010Escamilla EA Lewis GJ Bedard RL. Zirconium silicate molecular sieves and process for using the same. U.S. Patent 5\u2003888\u2003472; March 30 1999."},{"key":"e_1_2_5_32_2","unstructured":"Bem DS Sherman JD Napolitano A Leon\u2010Escamilla EA Lewis GJ Bedard RL. Zirconium silicate and zirconium germanate molecular sieves and process using the same. U.S. Patent 5\u2003891\u2003417; April 6 1999."},{"key":"e_1_2_5_33_2","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.1991.03470080067031","article-title":"A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram\u2010negative sepsis. The Xoma sepsis study group.","volume":"266","author":"Greenman RI","year":"1991","journal-title":"JAMA"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199102143240701"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199422110-00005"},{"key":"e_1_2_5_36_2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis.","volume":"8","author":"Bernard GR","year":"2001","journal-title":"N Engl J Med"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.8.2.8119492"},{"key":"e_1_2_5_38_2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1681\/ASN.V52228","article-title":"Proinflammatory cytokines and hemofiltration membranes.","volume":"5","author":"Goldfarb S","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_5_39_2","first-page":"89","volume-title":"Continuous extracorporeal treatment in multiple organ dysfunction syndrome","author":"Braun N","year":"1995"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01726541"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002480-199809000-00072"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1594.1999.06232.x"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002480-199805000-00004"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2000.00192.x"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/039139889902200310"}],"container-title":["Therapeutic Apheresis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1526-0968.2001.00384.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1526-0968.2001.00384.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T05:55:44Z","timestamp":1697522144000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1526-0968.2001.00384.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["10.1046\/j.1526-0968.2001.00384.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1526-0968.2001.00384.x","archive":["Portico"],"relation":{},"ISSN":["1091-6660","1526-0968"],"issn-type":[{"value":"1091-6660","type":"print"},{"value":"1526-0968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10]]}}}